Rigel Pharmaceuticals, Inc.

1180 Veterans Boulevard
South San Francisco
California
94080
United States

Tel: 650-624-1100
Fax: 650-624-1101

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Rigel's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy. In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

296 articles with Rigel Pharmaceuticals, Inc.

Rigel Welcomes Gregg Lapointe to Board of Directors

11/2/2017

Currently the CEO and co-founder of Cerium Pharma, Mr. Lapointe offers Rigel's board nearly three decades of commercial and financial experience bringing products to market in the areas of medical devices and rare diseases.
Rigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results

10/31/2017

Rigel today announced that it will report its third quarter financial results after market close on Tuesday, November 7, 2017.
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

10/11/2017
Rigel Announces Pricing Of Public Offering Of Common Stock

10/5/2017
Rigel Announces Proposed Public Offering Of Common Stock

10/4/2017
Rigel Release: Fostamatinib Meets Pre-Specified Primary Endpoint In Stage 1 Of Autoimmune Hemolytic Anemia (AIHA) Phase II Study

10/3/2017
Rigel Provides Update On FDA Review Of Fostamatinib For ITP

10/2/2017
Rigel Welcomes Brian Kotzin, M.D. To Board Of Directors

8/25/2017
Rigel Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

8/21/2017
Rigel Announces Second Quarter 2017 Financial Results And Provides Company Update

8/2/2017
Rigel Announces Conference Call And Webcast To Report Second Quarter 2017 Financial Results

7/25/2017
FDA Accepts Rigel's New Drug Application For TAVALISSE (Fostamatinib Disodium) For The Treatment Of Chronic ITP

6/19/2017
Rigel: Tavalisse NDA Will Be A Game-Changer

5/26/2017
Rigel Announces First Quarter 2017 Financial Results And Provides Company Update

5/3/2017
Rigel Announces Tavalisse As Proprietary Name For Fostamatinib In The United States

4/27/2017
Rigel Announces Conference Call And Webcast To Report First Quarter 2017 Financial Results

4/25/2017
Rigel Submits New Drug Application To FDA For Fostamatinib In Chronic ITP

4/18/2017
Rigel Announces Fourth Quarter 2016 And Year End 2016 Financial Results And Provides Company Update

3/8/2017
Rigel Announces Conference Call And Webcast To Report Fourth Quarter And Year End 2016 Financial Results

2/28/2017
Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

2/6/2017